Rates of irAE (unrelated to pre-existing autoimmune disease)
| No (%) | Details | |
| irAE | ||
| No | 18 (33) | |
| Yes | 37 (67) | |
| irAE grade | ||
| G1, 2 | 16(43) | Colitis—5, hepatitis—2, hypophysitis—4, thyroiditis—2, rash, arthritis, type 1 diabetes |
| G3 | 15 (27) | Colitis—7, hepatitis—3, colitis+hepatitis—2*, pneumonitis—2, thyroiditis |
| G4 | 6 (15) | Colitis—2, hepatitis—2, Guillain-Barre syndrome, myasthenia gravis |
| Immunosuppression for irAE | ||
| Oral steroids | 7 (19) | |
| IV steroids | 7 (19) | |
| Steroid and SSA | 9 (24) | Colitis—4, hepatitis—3, colitis+hepatitis—2 |
| IVIg | 1 (3) | Guillain-Barre syndrome |
| Plasmapheresis | 1 (3) | Myasthenia gravis |
| IO dosing after irAE | ||
| Both drugs ceased | 15 (41) | Colitis—6, hepatitis—3, colitis+hepatitis—2, pneumonitis, Guillain-Barre syndrome, myasthenia gravis, type 1 diabetes mellitus |
| Anti-PD1 continued alone | 2 (5) | |
| Anti-CTLA4 continued alone | 3 (8) | |
| Both continued | 17 (46) |
*Two patients experienced both grade 3 colitis and hepatitis.
irAE, immune-related adverse event; IVIg, intravenous immunoglobulin; SSA, steroid-sparing agent.